Acurx Pharmaceuticals Inc. has announced the advancement of its lead antibiotic candidate, ibezapolstat, to international pivotal Phase 3 clinical trials for the treatment of C. difficile infection $(CDI.NZ)$. The company has been working in collaboration with Leiden University Medical Center (LUMC) to study the mechanism of action of DNA pol IIIC inhibitors. Results from this collaboration were presented at a scientific conference on May 21 by Dr. Mia Urem from LUMC. These findings provide insight into the structural biology of DNA pol IIIC in complex with inhibitors, which is crucial for developing this new class of antibiotics aimed at treating resistant gram-positive infections. Acurx's Executive Chairman, Bob DeLuccia, emphasized the importance of these data in guiding the design of new compounds to combat antimicrobial resistance. Further details of the presentation are available on the company's website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.